Abstract

Author(s): Qiong Wu, X. P. Liao, Qin Zou, Chen Ting Li and Y. Cui*
Department of Nephrology, The First Peoples’ Hospital of Chenzhou, 1Department of Nephrology, The First Affiliated Hospital of Xiangnan University, 2Department of Nephrology, Chenzhou Hospital Affiliated to University of South China, Chenzhou 423000, Hunan Province, 3Department of Otorhinolaryngology Head and Neck Surgery, The First Peoples’ Hospital of Chenzhou, Chenzhou 423000, Hunan Province, 4Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Xiangnan University, Chenzhou 423000, Hunan Province, China

Correspondence Address:
Y. Cui, Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Xiangnan University, Chenzhou 423000, Hunan Province, China, E-mail: sanlongtree@126.com

This study summarizes the efficacy of roxadustat for secondary hyperparathyroidism. 65 individuals with secondary hyperparathyroidism were selected between May 2022 and May 2023 and were divided into control (n=30) and observation groups (n=35). The control group was treated with iron polysaccharide complex capsules+erythropoietin while the observation group was given roxadustat. Comparative analysis was conducted in terms of efficacy, drug safety which included fatigue, nausea and vomiting, myodynia and hypercalcemia. Further, serum biochemical indices like red blood cell count, hematocrit value and hemoglobin concentration were observed and compared. Then, microinflammation indicators like C-reactive protein, beta 2-microglobulin and interleukin-6 were also evaluated. Finally, the quality of life according to the World Health Organization quality of life was evaluated. The results revealed markedly higher efficacy, and a comparable incidence of adverse drug events in the observation group compared with the control group. In addition, the observation group had evidently elevated red blood cell count, hematocrit value, hemoglobin and World Health Organization quality of life scores compared with the baseline and the control group, as well as significantly higher reduced C-reactive protein, beta 2-microglobulin and interleukin-6. It can be concluded that, roxadustat is effective and safe for secondary hyperparathyroidism patients which can ameliorate anemia-related indicators and the microinflammation indicators can enhance the quality of life.

Full-Text | PDF